Immunotherapy combo shows promise for bladder cancer patients unable to get chemo
NCT ID NCT02812420
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how the drugs affect the immune system and tumor. It is not yet known if this approach improves outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab and Tremelimumab (immunotherapy drugs)
- What this could lead to
- If successful, this could offer a new pre-surgery treatment option for bladder cancer patients who cannot tolerate standard chemotherapy.
- What could go wrong
- This is a very early, small pilot study focused on safety, not effectiveness. The drugs may cause immune-related side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYDRONEPHROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for advanced bladder cancer? bevacizumab combo tested
- Real-World data sought on nivolumab for bladder cancer after surgery
- AI could help babies avoid unnecessary kidney surgery
- New ultrasound technique could prevent unnecessary treatments in pregnant women with kidney swelling
- New study aims to uncover nerve side effects of cancer drug
- New drug combo targets Hard-to-Treat bladder cancer